subject: Niaspan Er - Side Effects, Dosage, Interactions [print this page] Because clinical studies are conducted under wide varied conditions, adverse response rates noted in the clinical studies of a drug cannot be straightaway compared to ranges in the impersonal studies of another drug and may not reflect the charge per units observed in use.
Clinical Studies Experience
In the placebo-controlled nonsubjective trials database of 422 patient roles (age range 23-72 years, 32% women, 39% Caucasians, 7% Pitch Blacknesses, 1% Hispanics, 3% Asians) with a natural handling duration of 13 weeks, 13% of patients on Niaspan side effects and 3% of affected roles on placebo quit due to adverse chemical reactions. The most common adverse responses in the group of patients treated with side effects of Niaspan that leaved to handling discontinuation and came at a rate larger than placebo were evening out (1% vs. 0%), rash (3% vs. 5%), diarrhea (3% vs. 5%), nausea (5% vs. 3%), and vomiting (1% vs. 2%). The most unremarkably reported adverse chemical reactions (incidence >5% and greater than placebo) in the Niaspan learned clinical trial database of 402 affected roles were flushing, diarrhoea, nausea, spewing, increased cough and pruritus.
In the placebo-controlled verifiable trials, flushing episodes (i.e., passion, redness, itching and/or tingling) were the most low treatment-emergent unfavourable reactions (reported by as many an as 81% of patients) for Niaspan side effects. Spontaneous reports propose that blushing may also be attended by symptoms of vertigo, tachycardia, shakinesses, shortness of breath, sweating, burning sensation/skin serious sensation, chills, and/or edema, which in rare cases may lead to syncopation. In pivotal studies, 6% (12/245) side effects of Niaspan affected roles quit due to blushing. In comparisons of immediate-release (IR) niacin side effects and Niaspan, although the balance of affected roles who flushed was like, fewer flushing sequences were reported by patient roles who received side effects of Niaspan. Following 1 weeks of criminal maintenance therapy at daily dots of 1520 milligram, the incidence of leveling over the 2-week menstruation averaged out 8.3 events per tolerant for IR side effects of niacin versus 1.2 chase Niaspan.
The keeping an eye on additional adverse responses have been identified during post-approval use of Niaspan:
Hypersensitivity responses, including anaphylaxis, angioedema, urticaria, flushing, dyspnea, tongue edema, larynx oedema, face edema, peripheral edema, laryngismus, and vesiculobullous rash; maculopapular blizzard; dry bark; tachycardia; palpitations; atrial fibrillation; past cardiac cardiac arrhythmias; syncope; hypotension
